PRIMARY STUDY

Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection

Key Findings:  Increasing evidence suggests a prominent modulatory function of the cannabinoid signaling system in the basal ganglia. Hence, use of cannabinoids as a new therapeutic target has been recommended as a promising therapy for PD.

Type of Study:  Meta-analysis

Study Result:  Positive


Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), CP-x Synthetic Cannabinoids, HU-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Other Related Compounds

Phytocannabinoid Source:  Not Applicable

Form of Administration:  Not Applicable

Receptors Studied:  CB1, CB2, GPCR 55, TRPV1

Ligands Studied:  Anti-inflammatory cytokines, Dopamine, GABA, Glutamate, Pro-inflammatory cytokines


Study Location(s):  South Korea

Year of Pub:  2015


Link to study